表紙
市場調查報告書

組織胺H4受體:開發中產品分析

Histamine H4 Receptor - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 359402
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
組織胺H4受體:開發中產品分析 Histamine H4 Receptor - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 52 Pages
簡介

本報告提供組織胺H4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

組織胺H4受體概要

治療藥的開發

組織胺H4受體:開發中的產品 - 各開發階段

組織胺H4受體:開發中的產品 - 各治療範圍

組織胺H4受體開發中的產品 - 各適應症

組織胺H4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組織胺H4受體:企業開發中的產品

組織胺H4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組織胺H4受體的治療藥開發企業

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • Ziarco Pharma Ltd

組織胺H4受體:藥物簡介

組織胺H4受體:暫停中的計劃

組織胺H4受體:開發中止的產品

組織胺H4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2352TDB

Summary:

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 7 molecules. The latest report Histamine H4 Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 4 respectively. Report covers products from therapy areas Dermatology, Immunology, Ear Nose Throat Disorders, Ophthalmology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergies, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis and Plaque Psoriasis (Psoriasis Vulgaris).

Furthermore, this report also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
  • Bioprojet SCR
  • Chrysalis Pharma SAS
  • JW Pharmaceutical Corp
  • Novartis AG
  • Sensorion SA
  • Sosei Heptares
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
  • adriforant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • azasetron - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 16, 2020: Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
  • Feb 18, 2020: Sensorion gets approval to add new sites to Phase II trial of SENS-401
  • Feb 03, 2020: Sensorion to attend and present at LSX World Congress 2020
  • Jan 30, 2020: Sensorion presents new SENS-401 preclinical data at ARO Midwinter Meeting 2020
  • Jan 10, 2020: Sensorion announces its presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
  • Dec 23, 2019: Sensorion announces positive data safety monitoring board review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss
  • Dec 23, 2019: Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study
  • Nov 20, 2019: Drug tested for sudden hearing loss
  • Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover
  • Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago
  • Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua
  • Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
  • Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)
  • Jun 28, 2019: Sensorion's PIP is EMA-approved for two indications
  • Mar 31, 2019: JW Pharmaceutical receives the Technology Export Award of the 20th Republic of Korea New Drug Development Awards
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Bioprojet SCR, H1 2020
  • Pipeline by Chrysalis Pharma SAS, H1 2020
  • Pipeline by JW Pharmaceutical Corp, H1 2020
  • Pipeline by Novartis AG, H1 2020
  • Pipeline by Sensorion SA, H1 2020
  • Pipeline by Sosei Heptares, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020